Monoclonal antibodies against microorganisms

Abstract

The recent spread of hybridoma technology among laboratories has promoted the development of monoclonal antibodies against a wide variety of infectious disease agents. While monoclonal antibodies theoretically represent an excellent (perhaps superior) alternative to conventional antisera as diagnostic, therapeutic or laboratory reagents, traditional antisera may be preferable to monoclonal antibody in some circumstances because of the fixed affinity and specificity as well as the limited functional capacities of some antibodies. The acceptance of monoclonal antibodies by the clinical microbiologist and physician must await proof of their reliability, safety and efficacy.